Cyclacel Pharmaceuticals Profit Margin 2006-2021 | CYCC
Current and historical gross margin, operating margin and net profit margin for Cyclacel Pharmaceuticals (CYCC) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Cyclacel Pharmaceuticals net profit margin as of June 30, 2021 is 0%.
|Cyclacel Pharmaceuticals Annual Profit Margins
|Cyclacel Pharmaceuticals Quarterly Profit Margins
||Medical - Biomedical and Genetics
CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer.